6 Ways Orphan Drug Companies Can Regain Public Trust…while Also Ensuring Return on Investment!
Companies that dabble in the orphan drug space should be getting lots of attention, but sadly they seem to be getting it for all of the wrong reasons. Articles like this are becoming more and more common, even while more and more orphan indications are gaining treatments. All of this in an industry where the pharmaceutical companies of the world were some of the most trusted and looked up to firms in the country – our great scientists working together to save the world. Today, however, you are more likely to hear about greed and drug money rather than generosity and scientific achievement.
So where is all of this recent ire being drawn from? There are several complex factors at play, but here are some ways that orphan drug companies, and in many ways pharmaceutical companies in general, can work to regain public trust while not losing out on their ability to recoup their losses – all based on information, interviews, and feedback from experts in the industry.
Download the eBook now to find our 6 ways that Orphan Drug Companies can Regain Public Trust >
Information for this book was provided by payers, pharma, regulators, and other participants taking part in the World Orphan Drug Congress USA.
Continue the Discussion at World Orphan Drug Congress USA 2015. The pricing and sustainability arguments, as well as some dynamic interaction between payers and pharma, will be taking place at this year’s event.